ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) is one of 1,070 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare ArriVent BioPharma to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for ArriVent BioPharma and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ArriVent BioPharma | 0 | 0 | 5 | 0 | 3.00 |
ArriVent BioPharma Competitors | 8271 | 22032 | 50052 | 1335 | 2.54 |
ArriVent BioPharma presently has a consensus price target of $39.40, suggesting a potential upside of 87.62%. As a group, “Pharmaceutical preparations” companies have a potential upside of 215.92%. Given ArriVent BioPharma’s competitors higher probable upside, analysts plainly believe ArriVent BioPharma has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
Volatility & Risk
ArriVent BioPharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, ArriVent BioPharma’s competitors have a beta of 3.74, suggesting that their average share price is 274% more volatile than the S&P 500.
Profitability
This table compares ArriVent BioPharma and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ArriVent BioPharma | N/A | -43.89% | -29.67% |
ArriVent BioPharma Competitors | -3,399.87% | -235.11% | -32.77% |
Earnings and Valuation
This table compares ArriVent BioPharma and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
ArriVent BioPharma | N/A | -$69.33 million | -8.17 |
ArriVent BioPharma Competitors | $9.94 billion | $137.22 million | -7.59 |
ArriVent BioPharma’s competitors have higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
ArriVent BioPharma competitors beat ArriVent BioPharma on 8 of the 13 factors compared.
About ArriVent BioPharma
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.